S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

$20.74
-0.54 (-2.54%)
(As of 04/17/2024 ET)
Today's Range
$20.58
$21.55
50-Day Range
$21.22
$24.57
52-Week Range
$11.22
$25.34
Volume
1.78 million shs
Average Volume
1.16 million shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.42

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
65.9% Upside
$34.42 Price Target
Short Interest
Bearish
11.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.70) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

369th out of 913 stocks

Pharmaceutical Preparations Industry

152nd out of 400 stocks

SNDX stock logo

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

SNDX Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
SNDX Apr 2024 17.500 put
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/18/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNDX
Employees
184
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.42
High Stock Price Target
$45.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+65.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-209,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$6.53 per share

Miscellaneous

Free Float
81,481,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
1.03
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael A. Metzger M.B.A.Mr. Michael A. Metzger M.B.A. (Age 53)
    CEO & Director
    Comp: $1.1M
  • Dr. Peter Ordentlich B.Sc. (Age 55)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Dr. Richard A. Heyman Ph.D. (Age 67)
    Co-Founder
  • Dr. Ronald M. Evans Ph.D. (Age 75)
    Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D.
    Co-Founder
  • Sharon Klahre
    Vice President of Investor Relations & Communications
  • Mr. Kevin McManus (Age 55)
    Chief People Officer
  • Dr. Joseph Paul Eder M.D.
    Member of Scientific Advisory Board & Chief Medical Officer
  • Dr. Anjali Ganguli Ph.D. (Age 47)
    Chief Business Officer
    Comp: $450.58k
  • Mr. Steven Closter
    Chief Commercial Officer

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price target for 2024?

10 brokers have issued 1-year price targets for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $23.00 to $45.00. On average, they expect the company's stock price to reach $34.42 in the next twelve months. This suggests a possible upside of 65.9% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2024?

Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX stock has decreased by 4.0% and is now trading at $20.74.
View the best growth stocks for 2024 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its earnings results on Tuesday, February, 27th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same period in the prior year, the business earned ($0.62) EPS.

What ETFs hold Syndax Pharmaceuticals' stock?
What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners